Akebia Therapeutics, Inc.
DE ˙ DB ˙ US00972D1054
0,83 € ↓ -0,02 (-2,69%)
2026-06-03
AKTIENPREIS
SecurityDE:AX9 / Akebia Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership11,614,006 shares
Ownership 4.30%
State Street Corp ownership in AX9 / Akebia Therapeutics, Inc.

2026-05-12 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 11,614,006 shares of Akebia Therapeutics, Inc. (DE:AX9). This represents 4.3 percent ownership of the company. In their previous filing dated 2026-02-09 , State Street Corp had reported owning 13,687,561 shares, indicating a decrease of -15.15 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-05-12 2026-05-12 13G 13,687,561 11,614,006 -15.15 4.30 -17.31
2026-02-09 2026-02-09 13G 571,936 13,687,561 2,293.20 5.20 1,577.42
2023-01-20 2023-01-20 13G/A 11,743,461 571,936 -95.13 0.31 -95.38
2022-02-10 2022-02-10 13G/A 14,006,637 11,743,461 -16.16 6.71 -23.31
2021-07-12 2021-07-12 13G/A 22,476,534 14,006,637 -37.68 8.75 -43.73
2021-02-11 2021-02-11 13G 22,817,170 22,476,534 -1.49 15.55 -1.52
2021-02-10 2021-02-10 13G/A 15,340,471 22,817,170 48.74 15.79 47.57
2020-10-13 2020-10-13 13G/A 15,340,471 10.70

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AKEBIA THREAPEUTICS COM 00972D105 11,614,006 -2,073,555 -15.15 16,143 -26.74 0.0006
2026-02-13 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 13,687,561 1,842,792 15.56 22,037 -31.85 0.0007
2025-11-14 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 11,844,769 3,847,616 48.11 32,336 11.09 0.0011
2025-08-14 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 7,997,153 1,191,346 17.50 29,110 122.77 0.0011
2025-05-15 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 6,805,807 501,109 7.95 13,067 9.09 0.0005
2025-02-14 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 6,304,698 2,874,171 83.78 11,979 164.53 0.0005
2024-11-14 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 3,430,527 683,287 24.87 4,528 61.60 0.0002
2024-08-14 2024-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 2,747,240 2,096,890 322.42 2,802 135.46 0.0001
2024-05-15 2024-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 650,350 39,800 6.52 1,190 57.20 0.0001
2024-02-14 2023-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 610,550 -45,900 -6.99 757 1.20 0.0000
2023-11-14 2023-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 656,450 30,400 4.86 748 30.77 0.0000
2023-08-14 2023-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 626,050 -66,786 -9.64 573 47.42 0.0000
2023-05-15 2023-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 692,836 120,900 21.14 388 17.58 0.0000
2023-05-15 2022-12-31 13F/A-99 AKEBIA THERAPEUTICS COM 00972D105 571,936 0 0.00 330 82.32 0.0000
2023-05-15 2022-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 571,936 0 330 0.0000
2022-11-15 2022-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 571,936 -1,940 -0.34 181 -10.84 0.0000
2022-08-15 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 573,876 -10,914,348 -95.00 203 -97.54 0.0000
2022-05-16 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 11,488,224 -255,237 -2.17 8,247 -68.93 0.0004
2022-02-14 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 11,743,461 -4,112,967 -25.94 26,540 -41.88 0.0013
2021-11-15 2021-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 15,856,428 1,849,791 13.21 45,667 -13.97 0.0024
2021-08-16 2021-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 14,006,637 -3,037,539 -17.82 53,085 -7.99 0.0028
2021-07-09 2021-03-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 17,044,176 -5,432,358 -24.17 57,695 -8.32 0.0033
2021-05-17 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 17,044,176 -5,432,358 57,695 0.0033
2021-02-16 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 22,476,534 7,136,063 46.52 62,934 63.44 0.0039
2020-11-10 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 15,340,471 10,328,433 206.07 38,505 -43.43 0.0026
2020-08-14 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 5,012,038 1,595,108 46.68 68,063 162.79 0.0049
2020-06-19 2020-03-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 3,416,930 -25,066 -0.73 25,900 19.06 0.0023
2020-05-11 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 3,416,930 -25,066 25,900 2,274.5415
2020-02-06 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 3,441,996 -203,661 -5.59 21,753 52.21 0.0015
2019-11-14 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 3,645,657 -2,153,025 -37.13 14,291 -49.08 0.0011
2019-08-14 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 5,798,682 2,416,715 71.46 28,066 1.33 0.0021
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 3,381,967 744,121 28.21 27,698 89.88 0.0022
2019-02-12 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 2,637,846 356,704 15.64 14,587 -27.58 0.0013
2018-11-09 2018-09-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 2,281,142 350,738 18.17 20,143 4.55 0.0015
2018-08-14 2018-06-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 1,930,404 430,191 28.68 19,267 34.76 0.0016
2018-05-15 2018-03-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 1,500,213 13,974 0.94 14,297 -35.31 0.0012
2018-02-14 2017-12-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 1,486,239 197,353 15.31 22,100 -12.84 0.0018
2017-11-14 2017-09-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 1,288,886 341,998 36.12 25,355 86.38 0.0022
2017-08-14 2017-06-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 946,888 399,160 72.88 13,604 170.03 0.0012
2017-05-15 2017-03-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 547,728 16,147 3.04 5,038 -8.86 0.0004
2017-02-09 2016-12-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 531,581 17,817 3.47 5,528 18.91 0.0005
2017-01-13 2016-09-30 13F/A-1 AKEBIA THERAPEUTICS Common equity shares 00972D105 513,764 27,431 5.64 4,649 27.97 0.0005
2016-11-14 2016-09-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 513,764 4,649
2016-08-12 2016-06-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 486,333 63,562 15.03 3,633 -4.67 0.0004
2016-05-20 2016-03-31 13F/A-1 AKEBIA THERAPEUTICS Common equity shares 00972D105 422,771 118,561 38.97 3,811 -3.03 0.0004
2016-05-12 2016-03-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 422,771 3,811
2016-02-16 2015-12-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 304,210 27,072 9.77 3,930 46.70 0.0004
2015-11-16 2015-09-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 277,138 46,028 19.92 2,679 12.66 0.0003
2015-08-13 2015-06-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 231,110 127,816 123.74 2,378 107.69 0.0003
2015-05-15 2015-03-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 103,294 4,678 4.74 1,145 0.09 0.0001
2015-02-11 2014-12-31 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 98,616 23,407 31.12 1,144 -31.29 0.0001
2014-11-12 2014-09-30 13F/A-1 AKEBIA THERAPEUTICS Common equity shares 00972D105 75,209 2,227 3.05 1,665 -17.86 0.0002
2014-11-10 2014-09-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 75,209 1,665
2014-08-12 2014-06-30 13F AKEBIA THERAPEUTICS Common equity shares 00972D105 72,982 72,982 2,027 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.